换一批
第一作者：
Christian,Lienhardt
第一单位：
French National Research Institute for Sustainable Development, Montpellier, France.
作者：
Christian,Lienhardt [1]
;
Kelly E,Dooley [2]
;
Payam,Nahid [3]
;
Charles,Wells [4]
;
Theresa S,Ryckman [5]
;
Emily A,Kendall [5]
;
Gerry,Davies [6]
;
Grania,Brigden [7]
;
Gavin,Churchyard [8]
;
Daniela Maria,Cirillo [9]
;
Eugenia,Di Meco [10]
;
Ramya,Gopinath [11]
;
Carole,Mitnick [12]
;
Cherise,Scott [13]
;
Farhana,Amanullah [14]
;
Cathy,Bansbach [15]
;
Martin,Boeree [16]
;
Michael,Campbell [17]
;
Francesca,Conradie [18]
;
Angela,Crook [19]
;
Charles L,Daley [20]
;
Keertan,Dheda [21]
;
Andreas,Diacon [22]
;
Agnes,Gebhard [23]
;
Debra,Hanna [24]
;
Norbert,Heinrich [25]
;
Anneke,Hesseling [26]
;
David,Holtzman [4]
;
Mathilde,Jachym [27]
;
Peter,Kim [28]
;
Christoph,Lange [29]
;
Lindsay,McKenna [30]
;
Graeme,Meintjes [31]
;
Norbert,Ndjeka [32]
;
Nguyen Viet,Nhung [33]
;
Bern-Thomas,Nyang'wa [34]
;
Nicholas I,Paton [35]
;
Raghuram,Rao [36]
;
Michael,Rich [37]
;
Rada,Savic [3]
;
Ingrid,Schoeman [38]
;
Boitumelo Semete,Makokotlela [39]
;
Mel,Spigelman [40]
;
Eugene,Sun [40]
;
Elin,Svensson [16]
;
Phumeza,Tisile [38]
;
Francis,Varaine [41]
;
Andrew,Vernon [42]
;
Mukadi Ya,Diul [43]
;
Tereza,Kasaeva [44]
;
Matteo,Zignol [44]
;
Medea,Gegia [44]
;
Fuad,Mirzayev [44]
;
Samuel G,Schumacher [44]
作者单位：
French National Research Institute for Sustainable Development, Montpellier, France.
[1]
Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America (USA).
[2]
Institute for Global Health, University of California San Francisco, San Francisco, USA.
[3]
Bill & Melinda Gates Medical Research Institute, Boston, USA.
[4]
Infectious Disease Division, School of Medicine, John Hopkins University, Baltimore, USA.
[5]
Institute of Infection and Global Health, University of Liverpool, Liverpool, England.
[6]
The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
[7]
Aurum Institute, Johannesburg, South Africa.
[8]
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, Milan, Italy.
[9]
European Medicines Agency, Amsterdam, Kingdom of the Netherlands.
[10]
Division of Anti-Infectives, Food and Drug Administration, WashingtonDC, USA.
[11]
School of Medicine, Harvard Medical School, Boston, USA.
[12]
Unitaid, Geneva, Switzerland.
[13]
Indus Hospital, Karachi, Pakistan.
[14]
ChinaCat Enterprises, Gig Harbor, USA.
[15]
University Medical Center, Radboud University, Amsterdam, Kingdom of the Netherlands.
[16]
Clinton Health Access Initiative, Boston, USA.
[17]
Wits Health Consortium, Johannesburg, South Africa.
[18]
MRC Clinical Trials Unit, University College of London, London, England.
[19]
Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, USA.
[20]
Centre for Lung Infection and Immunity, University of Cape Town, Cape Town, South Africa.
[21]
TASK, Cape Town, South Africa.
[22]
KNCV, The Hague, Kingdom of the Netherlands.
[23]
Global Health Division, Bill & Melinda Gates Foundation, Seattle, USA.
[24]
Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU, Munich, Germany.
[25]
Desmond Tutu TB Centre, Stellenbosch University, Stellenbosch, South Africa.
[26]
Centre Hospitalier de Bligny, Fontenay-lès-Briis, Paris, France.
[27]
French National Research Institute for Sustainable Development, Montpellier, France.;Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America (USA).
[28]
French National Research Institute for Sustainable Development, Montpellier, France.;Institute for Global Health, University of California San Francisco, San Francisco, USA.
[29]
French National Research Institute for Sustainable Development, Montpellier, France.;Bill & Melinda Gates Medical Research Institute, Boston, USA.
[30]
French National Research Institute for Sustainable Development, Montpellier, France.;Infectious Disease Division, School of Medicine, John Hopkins University, Baltimore, USA.
[31]
French National Research Institute for Sustainable Development, Montpellier, France.;Institute of Infection and Global Health, University of Liverpool, Liverpool, England.
[32]
French National Research Institute for Sustainable Development, Montpellier, France.;The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
[33]
French National Research Institute for Sustainable Development, Montpellier, France.;Aurum Institute, Johannesburg, South Africa.
[34]
French National Research Institute for Sustainable Development, Montpellier, France.;Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, Milan, Italy.
[35]
French National Research Institute for Sustainable Development, Montpellier, France.;European Medicines Agency, Amsterdam, Kingdom of the Netherlands.
[36]
French National Research Institute for Sustainable Development, Montpellier, France.;Division of Anti-Infectives, Food and Drug Administration, WashingtonDC, USA.
[37]
French National Research Institute for Sustainable Development, Montpellier, France.;School of Medicine, Harvard Medical School, Boston, USA.
[38]
French National Research Institute for Sustainable Development, Montpellier, France.;Unitaid, Geneva, Switzerland.
[39]
French National Research Institute for Sustainable Development, Montpellier, France.;Indus Hospital, Karachi, Pakistan.
[40]
French National Research Institute for Sustainable Development, Montpellier, France.;ChinaCat Enterprises, Gig Harbor, USA.
[41]
French National Research Institute for Sustainable Development, Montpellier, France.;University Medical Center, Radboud University, Amsterdam, Kingdom of the Netherlands.
[42]
French National Research Institute for Sustainable Development, Montpellier, France.;Clinton Health Access Initiative, Boston, USA.
[43]
French National Research Institute for Sustainable Development, Montpellier, France.;Wits Health Consortium, Johannesburg, South Africa.
[44]
医学主题词
人类(Humans);抗结核药(Antitubercular Agents);世界卫生组织(World Health Organization);结核(Tuberculosis);结核, 抗多种药物性(Tuberculosis, Multidrug-Resistant);利福平(Rifampin);费用效益分析(Cost-Benefit Analysis);服药依从性(Medication Adherence)
DOI
10.2471/BLT.24.291881
PMID
39070602
发布时间
2024-09-26
- 浏览0
Bulletin of the World Health Organization
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
